Alessandro Testori
European Organisation for Research and Treatment of Cancer(NL)European Organisation for Research and Treatment of Cancer(BE)
Publications by Year
Research Areas
Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways, CAR-T cell therapy research, Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation(2011)7,653 cited
- → Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma(2011)4,451 cited
- → Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma(2017)1,368 cited
- → Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy(2016)1,305 cited
- → Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial(2015)1,248 cited
- → Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study(2014)973 cited